PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7903897

Managing resistant schizophrenia.

P L Huckle·S S Palia
View original source ↗Export metadata ↓

Abstract

Approximately 25% of patients with schizophrenia remain actively psychotic despite treatment with conventional antipsychotic medication. Many of these patients become new long-stay patients or are frequent readmissions to psychiatric hospitals. This article reviews some of the causes of treatment resistance and the management of this group of patients.

Explore related subjects

Antipsychotic AgentsChemotherapy, AdjuvantDrug CombinationsDrug ResistanceHumansSchizophreniaJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P L Huckle, S S Palia. Managing resistant schizophrenia.. https://pubmed.ncbi.nlm.nih.gov/7903897/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Differential pharmacology of atypical antipsychotics: clinical implications.

PURPOSE: Pharmacology of atypical antipsychotics and the clinical implications are reviewed. SUMMARY: Psychiatric disorders, such as schizophrenia and bipolar disorder, are often associated with poor outcomes. Atypical antipsychotics have become the standard of care for these disorders, and multiple agents have demonstrated efficacy for both acute and maintenance therapy. As a result of their differential pharmacologic properties, atypical antipsychotics have diverse clinical profiles, resulting in different liabilities for specific adverse events. These effects can, in turn, have an adverse impact on patient functionality, adherence to therapy, and overall health. CONCLUSION: Atypical antipsychotics have distinct pharmacological profiles which result in clinically meaningful differences in adverse effects. Clinicians should have a wide choice of agents available with which to optimize outcomes in the majority of patients with psychiatric disorders.

Antipsychotic Agents↗